ColoPan
Exploring how tumours respond to different treatments to support personalised cancer care
The ColoPan study aims to improve personalised treatment approaches for pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Due to their complex biology, genetic diversity and resistance mechanisms, these cancers can respond very differently to treatment, making it difficult to predict which therapies will be most effective for each individual. Building on an innovative approach known as Personalised Personalised Functional Profiling (PFP), researchers will combine detailed molecular analyses of patients’ tumours with drug testing on patient-derived tumour models (organoids) to better understand how different cancers respond to available treatments in different patients. Although the results of this study will not be used to guide participants’ treatment decision, they will help evaluate new approaches that could support more personalised cancer care in the future.
The ColoPan study is closely associated with the SOCS project – Luxembourg’s project dedicated specifically to CRC– benefiting from CRC samples collected under this national CRC reference programme.
About the study
Locations
9, rue Edward Steichen
L-2540 Luxembourg
Contact
Who can participate?
Eligible participants
The study is recruiting:
- Are 18 years of age or older.
- Willing and able to comply with the protocol for the duration of the study, including data and sample collection.
- Are scheduled for surgery or biopsy (primary tumour or metastasis) PDAC.
- Are willing and able to provide written informed consent.
Exclusion criteria
- Are pregnant, planning a pregnancy or breastfeeding
- Have known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
- Have any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise safety
What will participants do?
01.
Sign an informed consent form
This must be completed before any study procedures take place.
02.
Provide a blood sample
This will be collected during the inclusion visit.
03.
Allow the collection of remaining tissue samples
Researchers may collect tissue samples remaining from your routine surgery or biopsy, if available. No additional surgical procedure will be performed for the study.
04.
Provide clinical information
This will include information related to your diagnosis, treatment, and follow-up.
05.
Attend biannual follow-up visits
These will take place for up to 5 years, during which your clinical information will be updated.
Contact & location
Hôpitaux Robert Schuman (HRS) – Site Kirchberg
Hôpitaux Robert Schuman (HRS) – Site Kirchberg
9, rue Edward Steichen
L-2540 Luxembourg
Study team
Participating institutions
Funded by
Hôpitaux Robert Schuman (HRS)
Luxembourg Institute of Health (LIH)
University of Luxembourg (UL)
Fondation Cancer
Related news & updates
Small country, significant capacity
Luxembourg may be one of Europe’s smallest countries, but the Luxembourg Research Clinic demonstrates how its highly connected national network…
Joint action on personalised cancer medicine kicks off
Luxembourg's Research Clinic has been admitted as a full member of ECRIN, the European Clinical Research Infrastructure Network, opening access…
Related events
Clinical Research Luxembourg Conference
Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…